Zobrazeno 1 - 10
of 1 036
pro vyhledávání: '"secondary progressive multiple sclerosis"'
Publikováno v:
Неврология, нейропсихиатрия, психосоматика, Vol 16, Iss 0, Pp 88-90 (2024)
The article provides an analysis of modern methods of treatment of secondary progressive multiple sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations and without exacerbations) is siponimod. Clin
Externí odkaz:
https://doaj.org/article/801c56066d954331893c62e836625fab
Autor:
Clara G. Chisari, Umberto Aguglia, Maria Pia Amato, Roberto Bergamaschi, Antonio Bertolotto, Simona Bonavita, Vincenzo Brescia Morra, Paola Cavalla, Eleonora Cocco, Antonella Conte, Salvatore Cottone, Giovanna De Luca, Alessia Di Sapio, Massimo Filippi, Antonio Gallo, Claudio Gasperini, Franco Granella, Giacomo Lus, Davide Maimone, Giorgia Teresa Maniscalco, Girolama Marfia, Lucia Moiola, Damiano Paolicelli, Ilaria Pesci, Paolo Ragonese, Marco Rovaris, Giuseppe Salemi, Claudio Solaro, Rocco Totaro, Maria Trojano, Marika Vianello, Mauro Zaffaroni, Vito Lepore, Francesco Patti, Carlo Avolio, Roberto Balgera, Paola Banfi, Paolo Bellantonio, Placido Bramanti, Lorenzo Capone, Guido Cavalletti, Luca Chiveri, Raffaella Clerici, Marinella Clerico, Francesco Corea, Vincenzo Dattola, Francesca De Robertis, Giancarlo Di Battista, Simonetta Galgani, Maurizia Gatto, Maria Grazia Grasso, Matilde Inglese, Lorenzo Lo Russo, Francesco Ottavio Logullo, Renato Mantegazza, Alessandra Protti, Monica Rezzonico, Mariarosa Rottoli, Marco Salvetti, Elio Scarpini, Leonardo Sinisi, Maddalena Sparaco, Daniele Spitaleri, Tiziana Tassinari, Simone Tonietti, Paola Valentino, Franco Valzania, Simonetta Venturi
Publikováno v:
Neurotherapeutics, Vol 21, Iss 4, Pp e00363- (2024)
Treatment options for secondary progressive MS (SPMS) are limited, especially considering that the new drugs recently approved are licensed for actively relapsing patients. We aimed to compare the disability progression in a real-world cohort of SPMS
Externí odkaz:
https://doaj.org/article/26800f29a8714b44b0ce1491be5de728
Autor:
Verena Isabell Leussink, Manda Jankovic, Marie Groth, Katrin Schuh, Inessa Schwab Sauerbeck, Olaf Hoffmann
Publikováno v:
Brain and Behavior, Vol 14, Iss 6, Pp n/a-n/a (2024)
Abstract Background The revised Lublin classification offers a framework for categorizing multiple sclerosis (MS) according to the clinical course and imaging results. Diagnosis of secondary progressive MS (SPMS) is often delayed by a period of uncer
Externí odkaz:
https://doaj.org/article/954ea2297b7c425db81391a2d0ef1a74
Autor:
Krizia Sanna, Antonio Bruno, Sara Balletta, Silvia Caioli, Monica Nencini, Diego Fresegna, Livia Guadalupi, Ettore Dolcetti, Federica Azzolini, Fabio Buttari, Roberta Fantozzi, Angela Borrelli, Mario Stampanoni Bassi, Luana Gilio, Gianluca Lauritano, Valentina Vanni, Francesca De Vito, Alice Tartacca, Fabrizio Mariani, Valentina Rovella, Alessandra Musella, Diego Centonze, Georgia Mandolesi
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundSecondary progressive multiple sclerosis (SPMS) is defined by the irreversible accumulation of disability following a relapsing-remitting MS (RRMS) course. Despite treatments advances, a reliable tool able to capture the transition from RRM
Externí odkaz:
https://doaj.org/article/8487908276e1450781995b35527d24c5
Autor:
Massimo Filippi, Laura Ferrè, Chiara Zanetta, Caterina Rizzi, Gabriella Pessina, Francesco Assogna, Maria A. Rocca
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) reduce relapse frequency, magnetic resonance imaging (MRI) activity, and slow disability progression. Numerous DMTs are approved for relapsing forms of MS although real-world data on pati
Externí odkaz:
https://doaj.org/article/ef54c05740f2416b8afe67eb74d099e0
Autor:
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl
Publikováno v:
Neurology and Therapy, Vol 12, Iss 6, Pp 1961-1979 (2023)
Abstract Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary p
Externí odkaz:
https://doaj.org/article/e5bed912d1c24028a5e2841dc4079259
Publikováno v:
Consilium Medicum, Vol 25, Iss 2, Pp 95-100 (2023)
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity acco
Externí odkaz:
https://doaj.org/article/88dcd9e5d40947958cc5a9d2a973db28
Publikováno v:
International Journal of Molecular Sciences, Vol 25, Iss 6, p 3374 (2024)
Multiple sclerosis (MS) is a complex inflammatory disease affecting the central nervous system. Most commonly, it begins with recurrent symptoms followed by partial or complete recovery, known as relapsing–remitting MS (RRMS). Over time, many RRMS
Externí odkaz:
https://doaj.org/article/ba3332c5bafb44fda7eb0e7016c86b6c
Publikováno v:
Neurology Letters, Vol 2, Iss Supplementary 1 (20th Iranian Multiple Sclerosis Congress) (2023)
Background: Rituximab, a monoclonal antibody that targets and eliminates CD20+ B cells, has shown effectiveness in decreasing disease activity in patients with multiple sclerosis (pwMS). This study aimed to investigate disability, motor function, and
Externí odkaz:
https://doaj.org/article/79718b38a081409ea4a7eeddd291a3cd
Autor:
ZHANG Chao, GAO Xue
Publikováno v:
Zhenduanxue lilun yu shijian, Vol 21, Iss 06, Pp 669-676 (2022)
Multiple sclerosis(MS) is a chronic inflammatory disease of the central nervous system that involves demyelination and axonal degeneration. Usually, MS begins with a relapsing-remitting MS (RRMS) course, and approxi mately will develop into secondary
Externí odkaz:
https://doaj.org/article/014e0b0895414a35ab85ca7546d0c5d0